Causes of ineligibility in randomized controlled trials and long-term mortality in patients with non-ST-segment elevation acute coronary syndromes

International Journal of Cardiology

Volumn 124, Issue 1, 2008, Pages 86-91

  Bosch, Xavier ^a   Delgado, Victoria ^a   Verbal, Fernando ^a   Bórquez, Emiliano ^a   Loma Osorio, Pablo ^a   Díez Aja, Salvador ^a   Miranda Guardiola, Faustino ^a   Sanchís, Juan ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Acute coronary syndromes; Clinical trials; Mortality; Prognosis

Indexed keywords

ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; HEPARIN; NITRATE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTICOAGULATION; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL RESEARCH; CONTROLLED STUDY; CORONARY RISK; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT PARTICIPATION; PATIENT SELECTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION;

ACUTE CORONARY SYNDROME; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 38349088605     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.12.027     Document Type: Article

References (27)

1. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 338 (1998) 1498-1505
2. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 338 (1998) 1488-1497
3. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 339 (1998) 436-443
4. The Fragmin and Fast Revascularization during InStability in Coronary artery disease Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 354 (1999) 701-707
5. Simoons ML, GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 357 (2001) 1915-1924
6. Cannon C.P., Weintraub W.S., Demopoulos L.A., et al. Thrombolysis in myocardial infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 344 (2001) 1879-1887
7. Hasdai D., Behar S., Wallentin L., et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. The Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 23 (2002) 1190-1201
8. Fox K.A., Goodman S.G., Klein W., et al. Management of acute coronary syndromes. Variations in practice and outcome. Findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 23 (2002) 1177-1189
9. Jha P., Deboer D., Sykora K., and Naylor C.D. Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants: a population-based comparison. J Am Coll Cardiol 27 (1996) 1335-1342
10. Brown N., Melville M., Gray D., et al. Relevance of clinical trial results in myocardial infarction to medical practice: comparison of four year outcome in participants of a thrombolytic trial, patients receiving routine thrombolysis, and those deemed ineligible for thrombolysis. Heart 81 (1999) 598-602
11. Cohen M., Gensini G.F., Maritz F., et al. Prospective evaluation of clinical outcomes after acute ST-elevation myocardial infarction in patients who are ineligible for reperfusion therapy: preliminary results from the TETAMI registry and randomized trial. Circulation 108 Suppl III (2003) III-14-III-21
12. Bahit M.C., Cannon C.P., Antman E.M., et al. Thrombolysis In Myocardial Infarction. Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry. Am Heart J 145 (2003) 109-117
13. Bjorklund E., Lindahl B., Stenestrand U., et al. Outcome of ST-elevation myocardial infarction treated with thrombolysis in the unselected population is vastly different from samples of eligible patients in a large-scale clinical trial. Am Heart J 148 (2004) 566-573
14. Collet J.P., Montalescot G., Fine E., et al. Enoxaparin in unstable angina patients who would have been excluded from randomised pivotal trials. J Am Coll Cardiol 41 (2003) 8-14
15. Kandzari D.E., Roe M.T., Chen A.Y., et al. Influence of clinical trial enrolment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes. Am Heart J 149 (2005) 474-481
16. Al Suwaidi J., Reddan D.N., Williams K., et al. Platelet IIb/IIIa antagonism for the reduction of acute coronary syndrome events in a Global Organization Network. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 106 (2002) 974-980
17. Han J.H., Chandra A., Mulgund J., et al. Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. Am J Med 119 (2006) 248-254
18. Sachdev M., Sun J.L., Tsiatis A.A., Nelson C.L., Mark D.B., and Jollis J.G. The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease. J Am Coll Cardiol 43 (2004) 576-582
19. Nunez J.E., Nunez E., Facila L., et al. Prognostic value of Charlson comorbidity index at 30 days and 1 year after acute myocardial infarction. Rev Esp Cardiol 57 (2004) 842-849
20. Gross C.P., Mallory R., Heiat A., and Krumholz H.M. Reporting the recruitment process in clinical trials: who are these patients and how did they get there?. Ann Intern Med 137 (2002) 10-16
21. King S.B., Barnhart H.X., Kosinski A.S., et al. Angioplasty or surgery for multivessel coronary artery disease: comparison of eligible registry and randomized patients in the EAST trial and influence of treatment selection on outcomes. Am J Cardiol 79 (1997) 1453-1459
22. Eagle K.A., Goodman S.G., Avezum A., Budaj A., Sullivan C.M., and Lopez-Sendon J. Practice variation and missed opportunities for reperfusion in ST-segment elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 359 (2002) 373-377
23. Boyd C.M., Darer J., Boult C., Fried L.P., Boult L., and Wu A.W. Clinical practice guidelines and quality of care or older patients with multiple comorbid diseases. Implications for pay for performance. JAMA 294 (2005) 716-724
24. Masoudi F.A., Gross C.P., Wang Y., et al. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001. Circulation 112 (2005) 39-47
25. Juurlink D.N., Mamdani M.M., Lee D.S., et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 351 (2004) 543-551
26. Alexander K.P., Chen A.Y., Roe M.T., et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294 (2005) 3108-3116
27. O'Connor P.J. Adding value to evidence-based clinical guidelines. JAMA 294 (2005) 741-743